You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

177Lu rhPSMA-10.1

Showing 1 - 25 of 7,837
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Glen Burnie (177Lu-rhPSMA-10.1 injection,

Recruiting
  • Prostate Cancer
  • +5 more
  • 177Lu-rhPSMA-10.1 injection
  • 18F-rhPSMA-7.3 injection
  • Glen Burnie, Maryland
  • +3 more
Feb 2, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Atlanta (procedure, radiation, other, drug)

Not yet recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Biospecimen Collection
  • +6 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 25, 2023

Prostate Cancer Trial in Houston (177Lu rhPSMA-10.1, Degarelix)

Not yet recruiting
  • Prostate Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.1 GBq (30 mCi) of 177Lu-P17-087
  • 1.1 GBq (30 mCi) of 177Lu-P17-088
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 30, 2022

Solid Tumor, Unspecified, Adult Trial in Singapore (177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004

Not yet recruiting
  • Solid Tumor, Unspecified, Adult
  • 177Lu-LNC1004 Injection group 1 radionuclide therapy
  • +3 more
  • Singapore, Singapore
    National University Cancer Institute, Singapore National Univers
Feb 1, 2023

Nasopharyngeal Carcinoma Trial in Xiamen (177Lu-EB-LM3 1, 177Lu-EB-LM3 2)

Recruiting
  • SSTR2-positive Tumors
  • 177Lu-LNC1010 1
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 20, 2022

Cancer, Prostate Cancer, Metastatic Cancer Trial (177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended

Not yet recruiting
  • Cancer
  • +3 more
  • 177Lu-PSMA-I&T - escalating renal absorbed dose
  • 177Lu-PSMA-I&T - recommended phase 2 regime
  • (no location specified)
Jun 14, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
  • +2 more
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 6, 2022

Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma Trial in Australia (89Zr-TLX250, 177Lu-TLX250 and

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • 89Zr-TLX250
  • 177Lu-TLX250 and Peposertib
  • North Ryde, New South Wales, Australia
  • +4 more
May 22, 2023

Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) Trial ([68Ga]Ga-DPI-4452,

Not yet recruiting
  • Clear Cell Renal Cell Cancer (ccRCC)
  • +2 more
  • (no location specified)
Jan 20, 2023

Advanced Cancer, Clear Cell Renal Cell Carcinoma Trial in Houston (177Lu girentuximab, Nivolumab, Cabozantinib)

Not yet recruiting
  • Advanced Cancer
  • Clear Cell Renal Cell Carcinoma
  • 177Lu girentuximab
  • +3 more
  • Houston, Texas
    MD Anderson Cancer Center
Dec 15, 2022

Prostate Cancer Trial (Lutetium Lu 177 JH020002 Injection)

Not yet recruiting
  • Prostate Cancer
  • Lutetium Lu 177 JH020002 Injection
  • (no location specified)
Nov 14, 2023

Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma

Recruiting
  • Refractory Thyroid Gland Carcinoma
  • +3 more
  • 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 3, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11GBq of 177Lu-EB-PSMA-617, 2.00 GBq of 177Lu-EB-PSMA-617,

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11GBq of 177Lu-EB-PSMA-617
  • +2 more
  • Beijing, China
    Peking Union Medical College Hospital
May 6, 2022

Metastatic Castration-resistant Prostate Cancer Trial ([177Lu]Ludotadipep 3.7 GBq)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • [177Lu]Ludotadipep 3.7 GBq
  • (no location specified)
Jul 12, 2022

Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma Trial in Rochester (radiation, drug, procedure, other)

Recruiting
  • Grade 1 Meningioma
  • +4 more
  • Gallium Ga 68-DOTATATE
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 11, 2023

SCLC, Malignant Melanoma, Sarcoma Trial (GD2-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • SCLC
  • +2 more
  • GD2-SADA:177Lu-DOTA Complex
  • (no location specified)
May 4, 2022

Solid Tumor Trial in United States (68Ga-FAP-2286, 177Lu-FAP-2286)

Recruiting
  • Solid Tumor
  • Birmingham, Alabama
  • +5 more
Aug 26, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in San Francisco

Active, not recruiting
  • Castration Levels of Testosterone
  • +6 more
  • Lutetium Lu 177-PSMA-617
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Apr 11, 2022

Gastroenteropancreatic Neuroendocrine Tumor Trial in Stanford (Lutathera, Gallium 68 Dotatate, Computed Tomography (CT))

Suspended
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Stanford, California
    Stanford Cancer Institute Palo Alto
Sep 21, 2022

Metastatic Clear Cell Renal Cell Carcinoma, With Positive PSMA Expression at Tumor Sites Trial (177Lu-PSMA-1

Not yet recruiting
  • Metastatic Clear Cell Renal Cell Carcinoma
  • With Positive PSMA Expression at Tumor Sites
  • 177Lu-PSMA-1 (radiopharmaceutical)
  • (no location specified)
Sep 26, 2023

Neuroendocrine Tumor Trial in United States (Lutetium Lu 177 Dotatate, Peposertib)

Recruiting
  • Neuroendocrine Neoplasm
  • Biospecimen Collection
  • +4 more
  • Duarte, California
  • +3 more
Jan 12, 2023

GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease Trial in United States

Recruiting
  • GEP-NET
  • +6 more
  • Duarte, California
  • +3 more
Jul 28, 2022

Pancreatic Carcinoma, Tumors That Express CA 19-9 Trial in Scottsdale, New York (MVT-1075, MVT-5873)

Suspended
  • Pancreatic Carcinoma
  • Tumors That Express CA 19-9
  • Scottsdale, Arizona
  • +1 more
Aug 23, 2022